The evolution of platelet-directed pharmacotherapy.
The evolution of platelet directed pharmacotherapy in the prevention and treatment of patients with thrombotic disorders is based soundly on a rapidly expanding knowledge of platelet biology. Traditionally viewed, throughout most of its relatively brief history in medicine, as an anucleate, passive contributor to hemostasis, a more contemporary perspective acknowledges platelets as complex, multidimensional cells that participate actively in coagulation, vascular repair, angiogenesis and thrombosis within the micro and the macro-circulatory systems. Herein, we consider platelet-directed pharmacotherapy from these fundamental, biology-based exemplars--megakaryocytes, signal transduction and the platelet--coagulation protease interface. We also highlight the emerging biopharmacology platform of oligonucleotide platelet adhesion antagonists and their complementary antidotes.
Duke Scholars
Published In
DOI
EISSN
ISSN
Publication Date
Volume
Start / End Page
Related Subject Headings
- Thrombosis
- Signal Transduction
- Platelet Aggregation Inhibitors
- Oligonucleotides
- Megakaryocytes
- Humans
- History, 21st Century
- History, 20th Century
- Cardiovascular System & Hematology
- Blood Platelets
Citation
Published In
DOI
EISSN
ISSN
Publication Date
Volume
Start / End Page
Related Subject Headings
- Thrombosis
- Signal Transduction
- Platelet Aggregation Inhibitors
- Oligonucleotides
- Megakaryocytes
- Humans
- History, 21st Century
- History, 20th Century
- Cardiovascular System & Hematology
- Blood Platelets